PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :		(11) International Publication Number:	WO 00/19985
A61K 9/50	A2	(43) International Publication Date:	13 April 2000 (13.04.00)

(21) International Application Number: PCT/EP99/07298

(22) International Filing Date: 1 October 1999 (01.10.99)

(30) Priority Data:

9821298.8	1 October 1998 (01.10.98)	GB
9821299.6	1 October 1998 (01.10.98)	GB
9826654.7	3 December 1998 (03.12.98)	GB
9827624.9	16 December 1998 (16.12.98)	GB
9907822.2	6 April 1999 (06.04.99)	GB
9907823.0	6 April 1999 (06.04.99)	GB

(71) Applicant *(for all designated States except AT US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A–1230 Vienna (AT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: OGORKA, Jörg [DE/DE]; Im Steinbrunnen 19/3, D–79585 Steinen (DE). KALB, Oskar [DE/DE]; Belchenstrasse 7, D–79539 Lörrach (DE). SHAH, Rajen [US/US]; 98 Peregrine Drive, Voorhees, NJ 08043 (US). KHANNA, Satish, Chandra [CH/CH]; Spitzackerstrasse 6, CH–4103 Bottmingen (CH).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH–4002 Basel (CH).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: NEW SUSTAINED RELEASE ORAL FORMULATIONS

(57) Abstract

Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigmine, in a time–controlled manner.